This article gives an overview of the trial conducted in non-dialysis chronic kidney disease (CKD) patients to determine the safety and efficacy of the intravenous iron supplementation. Study Background The use of iron or erythropoiesis stimulating agent (ESA) therapy to manage anemia in patients with chronic kidney disease (CKD) has increased significantly in recent years. Randomized trials have (not longer than 8 weeks) shown that the intravenous (IV) iron therapy is more effective than oral in terms of replenishing the iron stores and improving the anemic condition of the patient on dialysis.
However, there are concerns over the safety of IV iron therapy where rapid release of large amounts of iron into the blood stream can generate 'free' iron in the circulation inducing oxidative stress. In this context clinical evidence about the safety and the efficacy of IV iron therapy in…
